| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/01/2023 | -3.04% | Stifel | $72 → $68 | Maintains | Hold |
| 07/13/2023 | 2.67% | Stifel | $78 → $72 | Downgrades | Buy → Hold |
| 07/11/2023 | — | Truist Securities | Upgrades | Hold → Buy | |
| 05/08/2023 | 14.07% | JP Morgan | → $80 | Upgrades | Neutral → Overweight |
| 05/04/2023 | -7.31% | Truist Securities | $70 → $65 | Maintains | Hold |
| 05/04/2023 | 21.2% | Wells Fargo | $100 → $85 | Maintains | Overweight |
| 05/01/2023 | 14.07% | Stifel | $65 → $80 | Upgrades | Hold → Buy |
| 04/26/2023 | -0.19% | Barclays | $105 → $70 | Downgrades | Overweight → Equal-Weight |
| 04/06/2023 | 14.07% | UBS | $87 → $80 | Maintains | Neutral |
| 02/21/2023 | 49.72% | Barclays | $90 → $105 | Maintains | Overweight |
| 02/16/2023 | 42.59% | Wells Fargo | $75 → $100 | Upgrades | Equal-Weight → Overweight |
| 02/02/2023 | -0.19% | Truist Securities | $50 → $70 | Maintains | Hold |
| 02/02/2023 | 14.07% | JP Morgan | $45 → $80 | Maintains | Neutral |
| 02/02/2023 | 6.94% | Wells Fargo | $60 → $75 | Maintains | Equal-Weight |
| 02/02/2023 | 31.18% | Raymond James | $56 → $92 | Maintains | Strong Buy |
| 01/31/2023 | -14.44% | Wells Fargo | $50 → $60 | Maintains | Equal-Weight |
| 01/31/2023 | 28.33% | Barclays | $75 → $90 | Maintains | Overweight |
| 11/08/2022 | 6.94% | Barclays | → $75 | Upgrades | Equal-Weight → Overweight |
| 11/03/2022 | -35.83% | JP Morgan | $80 → $45 | Maintains | Neutral |
| 11/03/2022 | -20.15% | Raymond James | $100 → $56 | Maintains | Strong Buy |
| 10/03/2022 | -28.7% | Wells Fargo | $75 → $50 | Maintains | Equal-Weight |
| 09/01/2022 | 6.94% | Wells Fargo | $85 → $75 | Maintains | Equal-Weight |
| 08/04/2022 | 22.63% | UBS | $92 → $86 | Maintains | Neutral |
| 08/04/2022 | 42.59% | Raymond James | $110 → $100 | Maintains | Strong Buy |
| 07/22/2022 | 31.18% | UBS | $125 → $92 | Downgrades | Buy → Neutral |
| 06/22/2022 | 21.2% | Wells Fargo | → $85 | Downgrades | Overweight → Equal-Weight |
| 06/14/2022 | 32.61% | Stifel | $116 → $93 | Maintains | Hold |
| 06/09/2022 | 63.98% | Wells Fargo | $130 → $115 | Maintains | Overweight |
| 06/09/2022 | 35.46% | JP Morgan | → $95 | Downgrades | Overweight → Neutral |
| 06/09/2022 | 56.85% | Raymond James | $125 → $110 | Maintains | Strong Buy |
| 06/08/2022 | 21.2% | Truist Securities | $185 → $85 | Downgrades | Buy → Hold |
| 06/02/2022 | 85.37% | Wells Fargo | $145 → $130 | Maintains | Overweight |
| 05/04/2022 | 78.24% | Raymond James | $150 → $125 | Maintains | Strong Buy |
| 05/04/2022 | 106.76% | Wells Fargo | $155 → $145 | Maintains | Overweight |
| 05/04/2022 | 85.37% | JP Morgan | → $130 | Upgrades | Neutral → Overweight |
| 05/04/2022 | 65.41% | Stifel | $130 → $116 | Downgrades | Buy → Hold |
| 04/21/2022 | 56.85% | Barclays | $150 → $110 | Downgrades | Overweight → Equal-Weight |
| 03/17/2022 | 128.15% | Wells Fargo | $170 → $160 | Maintains | Overweight |
| 03/14/2022 | 113.89% | Raymond James | $185 → $150 | Maintains | Strong Buy |
| 02/03/2022 | 163.8% | Raymond James | $195 → $185 | Maintains | Strong Buy |
| 01/05/2022 | 178.06% | Raymond James | $200 → $195 | Maintains | Strong Buy |
| 12/07/2021 | 156.67% | Wells Fargo | → $180 | Initiates Coverage On | → Overweight |
| 11/18/2021 | 192.31% | Barclays | → $205 | Initiates Coverage On | → Overweight |
| 09/28/2021 | 220.83% | Truist Securities | $250 → $225 | Maintains | Buy |
| 09/15/2021 | 185.18% | Raymond James | $230 → $200 | Maintains | Strong Buy |
| 08/05/2021 | 227.96% | Raymond James | $250 → $230 | Maintains | Strong Buy |
| 07/28/2021 | 213.7% | Stifel | → $220 | Initiates Coverage On | → Buy |
| 07/12/2021 | 256.48% | Truist Securities | $300 → $250 | Maintains | Buy |
| 06/24/2021 | 220.83% | UBS | → $225 | Initiates Coverage On | → Buy |
| 06/23/2021 | 256.48% | Raymond James | $305 → $250 | Maintains | Strong Buy |
| 06/02/2021 | 334.91% | Raymond James | $300 → $305 | Maintains | Strong Buy |
| 04/09/2021 | 327.78% | Raymond James | $290 → $300 | Maintains | Strong Buy |
| 02/04/2021 | 285% | Truist Securities | $250 → $270 | Maintains | Buy |
| 02/04/2021 | 313.52% | Raymond James | $274 → $290 | Maintains | Strong Buy |
| 01/11/2021 | 290.7% | Raymond James | $224 → $274 | Maintains | Strong Buy |
| 12/11/2020 | — | Raymond James | Upgrades | Market Perform → Strong Buy | |
| 07/30/2020 | 156.67% | SunTrust Robinson Humphrey | $155 → $180 | Maintains | Buy |
| 07/22/2020 | 121.02% | SunTrust Robinson Humphrey | $150 → $155 | Maintains | Buy |
| 05/26/2020 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 05/14/2020 | 113.89% | SunTrust Robinson Humphrey | $140 → $150 | Maintains | Buy |
| 05/07/2020 | 99.63% | SunTrust Robinson Humphrey | $115 → $140 | Maintains | Buy |
| 05/07/2020 | 116.74% | Raymond James | $130 → $152 | Maintains | Strong Buy |
| 03/16/2020 | 62.56% | Raymond James | → $114 | Upgrades | Market Perform → Strong Buy |
| 02/06/2020 | 63.98% | JP Morgan | $103 → $115 | Maintains | Neutral |
| 10/25/2019 | 54% | B of A Securities | → $108 | Upgrades | Neutral → Buy |
| 10/01/2019 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 05/02/2019 | 18.35% | B of A Securities | $81 → $83 | Downgrades | Neutral → Underperform |
| 05/02/2019 | — | B of A Securities | Downgrades | Neutral → Underperform | |
| 03/27/2019 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 01/31/2019 | -0.19% | JP Morgan | → $70 | Upgrades | Underweight → Neutral |
| 12/17/2018 | 1.24% | Raymond James | → $71 | Upgrades | Underperform → Outperform |
| 10/24/2018 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 08/24/2018 | -0.19% | JP Morgan | $85 → $70 | Maintains | Underweight |
| 08/01/2018 | 2.67% | B of A Securities | $77 → $72 | Maintains | Underperform |
What is the target price for Scotts Miracle Gro (SMG)?
The latest price target for Scotts Miracle Gro (NYSE: SMG) was reported by Stifel on August 1, 2023. The analyst firm set a price target for $68.00 expecting SMG to fall to within 12 months (a possible -3.04% downside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Scotts Miracle Gro (SMG)?
The latest analyst rating for Scotts Miracle Gro (NYSE: SMG) was provided by Stifel, and Scotts Miracle Gro maintained their hold rating.
When is the next analyst rating going to be posted or updated for Scotts Miracle Gro (SMG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Scotts Miracle Gro, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Scotts Miracle Gro was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.
Is the Analyst Rating Scotts Miracle Gro (SMG) correct?
While ratings are subjective and will change, the latest Scotts Miracle Gro (SMG) rating was a maintained with a price target of $72.00 to $68.00. The current price Scotts Miracle Gro (SMG) is trading at is $70.13, which is out of the analyst's predicted range.